Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) EBITDA (2016 - 2025)

Palisade Bio has reported EBITDA over the past 16 years, most recently at -$10.0 million for Q4 2025.

  • Quarterly EBITDA fell 195.12% to -$10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.1 million through Dec 2025, down 21.52% year-over-year, with the annual reading at -$18.1 million for FY2025, 21.52% down from the prior year.
  • EBITDA was -$10.0 million for Q4 2025 at Palisade Bio, down from -$2.9 million in the prior quarter.
  • Over five years, EBITDA peaked at -$2.3 million in Q1 2021 and troughed at -$32.9 million in Q2 2021.
  • The 5-year median for EBITDA is -$3.6 million (2024), against an average of -$5.3 million.
  • Year-over-year, EBITDA crashed 1584.2% in 2021 and then skyrocketed 89.13% in 2022.
  • A 5-year view of EBITDA shows it stood at -$3.0 million in 2021, then dropped by 27.59% to -$3.8 million in 2022, then grew by 18.04% to -$3.2 million in 2023, then decreased by 7.23% to -$3.4 million in 2024, then plummeted by 195.12% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's EBITDA are -$10.0 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.8 million (Q2 2025).